This invention relates to the field of molecular physiology. Specifically, this invention relates to the prevention and/or treatment of cancer. Leucine-rich alpha-2-glycoprotein (Lrg1) has been demonstrated to be expressed in a range of cancer cells. Antagonists of Lrg1 can be used to prevent and/or treat cancer by an effect on neoplastic cells.
